The safety of liposome bupivacaine following various routes of administration in animals

Girish P Joshi, Gary Patou, Vladimir Kharitonov, Girish P Joshi, Gary Patou, Vladimir Kharitonov

Abstract

Background: This report presents results from four preclinical studies evaluating safety and pharmacokinetics (PKs) of liposome bupivacaine following intravascular (intravenous [IV], intra-arterial [IA]), epidural, and intrathecal administration in dogs.

Methods: Intravascular administration was initially tested in a pilot study to determine maximum tolerated doses, and then in an expanded study of systemic adverse effects and PKs. An epidural study compared properties of liposome bupivacaine alone and in combination with lidocaine/epinephrine vs bupivacaine HCl. Another study assessed effects after intrathecal administration.

Results: In the initial intravascular studies, maximum doses at which no meaningful adverse events were observed with liposome bupivacaine were higher than for bupivacaine HCl (4.5 mg/kg IV vs 0.75 mg/kg IV, and 1.5 mg/kg IA vs 0.1 mg/kg IA, respectively). In the expanded intravascular study, there was no mortality or changes in pathology; adverse clinical signs included convulsions, lying on side, and decreased muscle tone (all were transient). In the epidural study, liposome bupivacaine was well tolerated at doses up to the highest dose tested (40 mg), with no evidence of spinal cord damage and with less motor blockade than bupivacaine HCl 15 mg. Intrathecal administration of liposome bupivacaine 40 mg was not associated with meaningful safety concerns and resulted in less motor blockade than bupivacaine HCl 15 mg. PK analyses showed that maximum plasma bupivacaine levels following administration of liposome bupivacaine (4.5 mg/kg IV and 40 mg epidural) were similar to maximum plasma bupivacaine levels following a threefold lower dose of bupivacaine HCl (1.5 mg/kg IV and 15 mg epidural).

Conclusion: Liposome bupivacaine has a favorable safety profile compared with bupivacaine HCl when administered to dogs via intravascular, epidural, and intrathecal routes. This favorable safety profile is likely related to the liposome-bound nature of bupivacaine in the liposome bupivacaine formulation.

Keywords: bupivacaine; drug administration routes; local anesthesia; spinal injections.

Figures

Figure 1
Figure 1
Plasma bupivacaine pharmacokinetic profile following intravenous administration of bupivacaine HCl 1.5 mg/kg versus liposome bupivacaine 4.5 mg/kg. Abbreviation: SD, standard deviation.
Figure 2
Figure 2
Plasma bupivacaine pharmacokinetic profile following epidural administration of bupivacaine HCl 15 mg versus liposome bupivacaine 40 mg (with and without lidocaine/epinephrine). Abbreviation: SD, standard deviation.
Figure 3
Figure 3
Plasma bupivacaine pharmacokinetic profile following intrathecal administration of bupivacaine HCl 15 mg versus liposome bupivacaine 40 mg. Abbreviation: SD, standard deviation.

References

    1. Joshi GP, Schug SA, Kehlet H. Procedure-specific pain management and outcome strategies. Best Pract Res Clin Anaesthesiol. 2014;28(2):191–201.
    1. American Society of Anesthesiologists Task Force on Acute Pain Management Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012;116(2):248–273.
    1. White PF, Kehlet H, Neal JM, Schricker T, Carr DB, Carli F. The role of the anesthesiologist in fast-track surgery: from multimodal analgesia to perioperative medical care. Anesth Analg. 2007;104(6):1380–1396.
    1. Neal JM, Bernards CM, Butterworth JF, 4th, et al. ASRA practice advisory on local anesthetic systemic toxicity. Reg Anesth Pain Med. 2010;35(2):152–161.
    1. Di Gregorio G, Neal JM, Rosenquist RW, Weinberg GL. Clinical presentation of local anesthetic systemic toxicity: a review of published cases, 1979 to 2009. Reg Anesth Pain Med. 2010;35(2):181–187.
    1. Ilfeld BM. Liposome bupivacaine in peripheral nerve blocks and epidural injections to manage postoperative pain. Expert Opin Pharmacother. 2013;14(17):2421–2431.
    1. Covino BG, Wildsmith JA. Clinical pharmacology of local anesthetic agents. In: Cousins MJ, Bridenbaugh PO, editors. Neural Blockade in Clinical Anesthesia and Management of Pain. Philadelphia, PA: Lippincott-Raven; 1998. pp. 97–128.
    1. Exparel [prescribing information] Parsippany, NJ: Pacira Pharmaceuticals, Inc; 2014.
    1. Viscusi ER, Sinatra R, Onel E, Ramamoorthy SL. The safety of liposome bupivacaine, a novel local analgesic formulation. Clin J Pain. 2014;30(2):102–110.
    1. Lambert WJ, Los K. DepoFoam multivesicular liposomes for the sustained release of macromolecules. In: Rathbone MJ, Hadgraft J, Roberts MS, Lane ME, editors. Modified-Release Drug Delivery Technology. New York, NY: Informa Healthcare; 2008. pp. 207–214.
    1. Chahar P, Cummings KC., 3rd Liposomal bupivacaine: a review of a new bupivacaine formulation. J Pain Res. 2012;5:257–264.
    1. Mantripragada S. A lipid based depot (DepoFoam technology) for sustained release drug delivery. Prog Lipid Res. 2002;41(5):392–406.
    1. Howell SB. Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology. Cancer J. 2001;7(3):219–227.
    1. Angst MS, Drover DR. Pharmacology of drugs formulated with DepoFoam™: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Clin Pharmacokinet. 2006;45(12):1153–1176.
    1. Bergese SD, Ramamoorthy S, Patou G, Bramlett K, Gorfine SR, Candiotti KA. Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia. J Pain Res. 2012;5:107–116.
    1. Schmidt WK, Patou G, Joshi GP. Evaluating therapeutic benefit in post-surgical analgesia requires global assessment: an example from liposome bupivacaine in hemorrhoidectomy. Hosp Pract. 2012;40(1):160–165.
    1. Minkowitz H, Matthews A, Puckett C, Melson T. Liposome bupivacaine in femoral nerve block: initial results from a phase 2/3 pivotal study; Poster presented at: Annual Meeting of the American Society of Regional Anesthesia and Pain Medicine; April 3–6, 2014; Chicago, IL.
    1. Ilfeld BM, Malhotra N, Furnish TJ, Donohue MC, Madison SJ. Liposomal bupivacaine as a single-injection peripheral nerve block: a dose-response study. Anesth Analg. 2013;117(5):1248–1256.
    1. Kharitonov V. A review of the compatibility of liposome bupivacaine with other drug products and commonly used implant materials. Postgrad Med. 2014;126(1):129–138.
    1. Switzer RC., 3rd Application of silver degeneration stains for neurotoxicity testing. Toxicol Pathol. 2000;28(1):70–83.
    1. Viscusi ER, Candiotti KA, Onel E, Morren M, Ludbrook GL. The pharmacokinetics and pharmacodynamics of liposome bupivacaine administered via a single epidural injection to healthy volunteers. Reg Anesth Pain Med. 2012;37(6):616–622.
    1. Carvalho B, Roland LM, Chu LF, Campitelli VA, 3rd, Riley ET. Single-dose, extended-release epidural morphine (DepoDur) compared to conventional epidural morphine for post-cesarean pain. Anesth Analg. 2007;105(1):176–183.
    1. Gambling D, Hughes T, Martin G, Horton W, Manvelian G. A comparison of Depodur™, a novel, single-dose extended-release epidural morphine, with standard epidural morphine for pain relief after lower abdominal surgery. Anesth Analg. 2005;100(4):1065–1074.
    1. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17(10):3110–3116.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi